Search Results

Biotech Beach

Turn Therapeutics Atopic Dermatitis Candidate Reduces Disease Severity by 57% In-Vivo

In a widely cited in-vivo model of atopic dermatitis, Turn Therapeutics’ atopic dermatitis candidate showed a dramatic reduction in disease severity versus placebo.

June 20, 2024

·

2 min read

Small Animal Imaging (In-Vivo) Market Expecting a Surge in Revenue of US$ 1,902 Million By 2032

The global small animal imaging (In-Vivo) market was valued at US$ 1,053 million in 2023.

May 2, 2024

·

7 min read

Deals

Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems

Bruker Corporation announced that it has acquired Spectral Instruments Imaging LLC, a leader in preclinical in-vivo optical imaging systems.

February 6, 2024

·

3 min read

Press Releases

Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic

September 25, 2024

·

7 min read

Genetown

InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced topline results from the company’s INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo’s investigational Neuro-Spinal Scaffold™, a bioresorbable scaffold-based device in development for patients with acute SCI.

March 9, 2023

·

3 min read

Pharm Country

Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to Enzalutamide

Nuvectis Pharma, Inc. today announced a publication in the Journal of Experimental Medicine (“JEM”) for NXP900 in an in-vivo model of metastatic castration resistant prostate cancer.

February 9, 2023

·

4 min read

Deals

InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

InVivo Therapeutics Holdings Corp. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company’s common stock.

October 7, 2022

·

6 min read

Biotech Beach

Zavation releases In-Vitro and In-Vivo Research Summary for its novel “LABYRINTH™"

Zavation Medical Products, an innovative designer and manufacturer of spinal implants, instruments, MIS procedural kits, and biologics headquartered in Flowood, MS, announced the results of its novel LABYRINTH™ technology in an In-Vitro and In-Vivo research project.

August 10, 2022

·

3 min read

Genetown

InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery

InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery.

June 8, 2022

·

3 min read

Business

InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the appointment of Heather M. Hamel, J.D. as its Chief Legal Officer and General Counsel.

July 13, 2022

·

3 min read